×
返回 Agenda
Part 5: Accelerating Drug Discovery and Development: How AI Is Transforming Biotechnology from Lab to Launch
Session Chair(s)
Michael Rosenblatt, MD
Advisory Partner
Ascenta Capital, United States
Michael Nally
Flagship Pioneering, CEO-Partner
Generate:Biomedicines. CEO, United States
Andrew Plump MD, PhD
President, Research and Development
Takeda, United States
Artificial intelligence (AI) is becoming pervasive and is influencing virtually ass aspects of life. Therefore, it is no surprise that AI is becoming an essential component in drug development, from discovery, research and clinical development including clinical trials and product launch and marketing. This session will discuss the role of AI in biotechnology and provide specific examples of how it is transforming the discovery and development process in the industry.